Drug Profile
Research programme: cardiovascular and metabolic disease therapeutics - Genfit/Pierre Fabre
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Genfit; Pierre Fabre
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders; Lipid metabolism disorders; Metabolic disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Lipid-metabolism-disorders in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-disorders in France